Davita - Cleveland Pd is a medicare approved dialysis facility center in Oklahoma City, Oklahoma and it has 8 dialysis stations. It is located in Oklahoma county at 1059 Se 82nd, Oklahoma City, OK, 73149. You can reach out to the office of Davita - Cleveland Pd at (405) 512-6912. This dialysis clinic is managed and/or owned by Davita. Davita - Cleveland Pd has the following ownership type - Profit. It was first certified by medicare in October, 2010. The medicare id for this facility is 372579 and it accepts patients under medicare ESRD program.
| Name | Davita - Cleveland Pd |
|---|---|
| Location | 1059 Se 82nd, Oklahoma City, Oklahoma |
| No. of Dialysis Stations | 8 |
| Medicare ID | 372579 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 1059 Se 82nd, Oklahoma City, Oklahoma, 73149 | |
| (405) 512-6912 | |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago
| NPI Number | 1003146382 |
| Organization Name | Home Dialysis Center |
| Doing Business As | Cleveland Nephrology, Pllc |
| Address | 1059 Se 82nd Oklahoma City, Oklahoma, 73149 |
| Phone Number | (405) 512-6912 |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago
| NPI Number | 1851621213 |
| Organization Name | Home Dialysis Center |
| Doing Business As | Cleveland Nephrologists, Pllc |
| Address | 1059 Se 82nd Oklahoma City, Oklahoma, 73149 |
| Phone Number | (405) 329-3830 |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 9 |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 35 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 283 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 100 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - Cleveland Pd with elevated calcium levels.
| Patients with hypercalcemia | 35 |
| Hypercalcemia patient months | 283 |
| Patients with Serumphosphor | 37 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 24 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
| Patients with Serumphosphor greater than 7 mg/dL | 22 |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 23 |
| Hospitalization Rate in facility | 172.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 420.2 |
| Hospitalization Rate: Lower Confidence Limit | 76.2 |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - Cleveland Pd were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 5.3 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 25.4 |
| Readmission Rate: Lower Confidence Limit | .2 |
News Archive
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A new study to be presented at CHEST Congress 2019 Thailand in Bangkok shows a significant decrease in teen driving accidents when school start is delayed. Researchers from Farwaniya Hospital in Kuwait and Boston Children's Hospital studied the impact of a 50-minute delay in high school start times in one of the largest school districts in the U.S.
Sex is one of the most difficult topics a parent can bring up with an adolescent, but a new study finds that parents who are taught specific communication skills can more readily tackle these conversations and sustain them over time.
› Verified 8 days ago